Tag: axonics
Axonics prevails in patent infringement lawsuit with Medtronic
Axonics has announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against the company in US...
US patent office rejects Axonics’ latest challenge to Medtronic patents
Medtronic has announced that the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office has affirmed the validity of claims...
Axonics receives CE-mark approval for fourth-generation rechargeable SNM therapy
Axonics has announced that the Axonics R20 rechargeable sacral neuromodulation (SNM) system has received CE-mark approval.
Axonics expects to commence sales of the R20 to...
Medtronic files complaint against Axonics to stop “unauthorised use” of neuromodulation...
Medtronic recently announced that it has filed a complaint with the US International Trade Commission (ITC), along with a parallel action in US District...
Axonics announces definitive agreement to be acquired by Boston Scientific
Axonics has announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for US$71 in cash per share,...
Axonics receives US FDA approval for fourth-generation rechargeable sacral neuromodulation system
Axonics has announced that the US Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation (SNM) system—a technology intended to provide...
Axonics gains Health Canada approval for fourth-generation rechargeable sacral neuromodulation system
Axonics has announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system as a treatment for bladder and bowel dysfunction.
The newly...
Axonics announces first patient implants in Canada with recharge-free sacral neuromodulation...
Axonics has announced the first patient implants in Canada with Axonics F15, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
The University...
Axonics files FDA premarket approval supplement for fourth-generation rechargeable neurostimulator
Axonics has filed a premarket approval (PMA) supplement with the US Food and Drug Administration (FDA) for its fourth-generation rechargeable sacral neuromodulation (SNM) implantable...
Axonics announces comprehensive launch of F15 recharge-free SNM system
Axonics today announced the comprehensive launch of the Axonics F15 across the USA. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system also...
Axonics receives FDA approval for new recharge-free sacral neuromodulation system
Axonics has announced that the US Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator, the...
Axonics announces two-year results from its ARTISAN-SNM study
Two-year results of Axonics’ ARTISAN-sacral neuromodulation (SNM) study demonstrate that patients implanted with the r-SNM system continue to receive clinically meaningful and statistically significant...
Axonics receives FDA approval for 3T full-body MRI scans
Axonics, a company that has developed and is commercialising novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has...
FDA approval for Axonics’ wireless patient Remote Control with SmartMRI technology
Axonics, a company that has developed implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has announced US Food and...
Axonics wins FDA approval for its next-generation implantable neurostimulator
Axonics has announced the US Food and Drug Administration (FDA) approval of its next-generation rechargeable implantable neurostimulator for its r-SNM system under a premarket approval...
FDA approval of Axonics’ enhanced neurostimulator programmer
Axonics announces US Food and Drug Administration (FDA) approval of an enhanced, second-generation programmer for its r-SNM system under a premarket approval (PMA) application...
Axonics granted six US patents and allowed three additional patents related...
Axonics has announced that the United States Patent and Trademark Office has issued or allowed Axonics nine US utility patents in 2019, along with...
Axonics provides survey results from Physician Seminar Series showcasing the recently...
Axonics, a medical technology company that has developed and is commercialising novel implantable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel...
Axonics announces US Food & Drug Administration approval for its sacral...
Axonics, a medical technology company that has developed and is commercialising novel implantable rechargeable sacral neuromodulation (SNM) devices for the treatment of bladder and...
Axonics announces first commercial US patient implanted with its sacral neuromodulation...
Axonics has announced the first US-based implantation of the Axonics r-SNM system subsequent to its clearance by the US Food & Drug Administration (FDA)...
Axonics provides full one-year results from ARTISAN-SNM pivotal study
Axonics announced the presentation of detailed one-year results from its ARTISAN rechargeable sacral neuromodulation (r-SMN) pivotal study at a plenary session at the joint...
Axonics announces agreement to supply sacral neuromodulation systems to leading urology...
Axonics has announced that it has entered into an exclusive agreement to supply the Axonics rechargeable sacral neuromodulation (r-SNM) system to Adult Pediatric Urology...
Axonics announces US FDA approval for its sacral neuromodulation system
Axonics, a medical technology company that has developed and is commercialising a novel implantable rechargeable sacral neuromodulation (SNM) device for the treatment of urinary and...
Axonics announces FDA approval for the use of full-body MRI for...
Axonics have announced that the Food & Drug Administration (FDA) approved the use of full-body magnetic resonance imaging (MRI) using 1.5 Tesla MRI scanners...
Welkin Health announces partnership to implement a programme to support commercialisation...
Welkin Health, a privately-held patient relationship management software company has announced that it is partnering with Axonics, a company focused on the design, development,...
Axonics granted full-body MR-conditional CE mark for its sacral neuromodulation system
Axonics has announced that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging conditional labelling for the Axonics r-SNM...
Axonics announce positive clinical data from its ARTISAN sacral neuromodulation pivotal...
Axonics has disclosed positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the US Food and Drug Administration (FDA)...
Axonics secures US$40M financing to commercialise neuromodulation device
Axonics has secured US$40 million to support commercialisation of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the...
